Postprocedural Antiplatelet Treatment after Emergent Carotid Stenting in Tandem Lesions Stroke: Impact on Stent Patency beyond Day 1.
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
09
10
2020
accepted:
10
11
2020
pubmed:
20
2
2021
medline:
10
7
2021
entrez:
19
2
2021
Statut:
ppublish
Résumé
Postprocedural dual-antiplatelet therapy is frequently withheld after emergent carotid stent placement during stroke thrombectomy. We aimed to assess whether antiplatelet regimen variations increase the risk of stent thrombosis beyond postprocedural day 1. Retrospective review was undertaken of all consecutive thrombectomies for acute stroke with tandem lesions in the anterior circulation performed in a single comprehensive stroke center between January 9, 2011 and March 30, 2020. Patients were included if carotid stent patency was confirmed at day 1 postprocedure. The group of patients with continuous dual-antiplatelet therapy from day 1 was compared with the group of patients with absent/discontinued dual-antiplatelet therapy. Of a total of 109 tandem lesion thrombectomies, 96 patients had patent carotid stents at the end of the procedure. The early postprocedural stent thrombosis rate during the first 24 hours was 14/96 (14.5%). Of 82 patients with patent stents at day 1, in 28 (34.1%), dual-antiplatelet therapy was either not initiated at day 1 or was discontinued thereafter. After exclusion of cases without further controls of stent patency, there was no significant difference in the rate of subacute/late stent thrombosis between the 2 groups: 1/50 (2%) in patients with continuous dual-antiplatelet therapy versus 0/22 (0%) in patients with absent/discontinued dual-antiplatelet therapy ( Discontinuation of dual-antiplatelet therapy was not associated with an increased risk of stent thrombosis beyond postprocedural day 1. Further studies are warranted to better assess the additional benefit and optimal duration of dual-antiplatelet therapy after tandem lesion stroke thrombectomy.
Sections du résumé
BACKGROUND AND PURPOSE
Postprocedural dual-antiplatelet therapy is frequently withheld after emergent carotid stent placement during stroke thrombectomy. We aimed to assess whether antiplatelet regimen variations increase the risk of stent thrombosis beyond postprocedural day 1.
MATERIALS AND METHODS
Retrospective review was undertaken of all consecutive thrombectomies for acute stroke with tandem lesions in the anterior circulation performed in a single comprehensive stroke center between January 9, 2011 and March 30, 2020. Patients were included if carotid stent patency was confirmed at day 1 postprocedure. The group of patients with continuous dual-antiplatelet therapy from day 1 was compared with the group of patients with absent/discontinued dual-antiplatelet therapy.
RESULTS
Of a total of 109 tandem lesion thrombectomies, 96 patients had patent carotid stents at the end of the procedure. The early postprocedural stent thrombosis rate during the first 24 hours was 14/96 (14.5%). Of 82 patients with patent stents at day 1, in 28 (34.1%), dual-antiplatelet therapy was either not initiated at day 1 or was discontinued thereafter. After exclusion of cases without further controls of stent patency, there was no significant difference in the rate of subacute/late stent thrombosis between the 2 groups: 1/50 (2%) in patients with continuous dual-antiplatelet therapy versus 0/22 (0%) in patients with absent/discontinued dual-antiplatelet therapy (
CONCLUSIONS
Discontinuation of dual-antiplatelet therapy was not associated with an increased risk of stent thrombosis beyond postprocedural day 1. Further studies are warranted to better assess the additional benefit and optimal duration of dual-antiplatelet therapy after tandem lesion stroke thrombectomy.
Identifiants
pubmed: 33602749
pii: ajnr.A6993
doi: 10.3174/ajnr.A6993
pmc: PMC8115381
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
921-925Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 by American Journal of Neuroradiology.
Références
Int J Stroke. 2021 Apr;16(3):342-348
pubmed: 32515696
JACC Cardiovasc Interv. 2018 Jul 9;11(13):1290-1299
pubmed: 29976365
Int J Cardiol. 2013 Jul 31;167(2):575-84
pubmed: 22360945
J Neurointerv Surg. 2021 Feb;13(2):141-145
pubmed: 32532859
J Neurol. 2015 Dec;262(12):2668-75
pubmed: 26345413
Eur J Neurol. 2018 Sep;25(9):1115-1120
pubmed: 29575634
Neuroradiology. 2015 Jun;57(6):589-98
pubmed: 25404414
Front Neurol. 2019 Feb 27;10:127
pubmed: 30873105
Stroke. 2006 Sep;37(9):2301-5
pubmed: 16888266
AJNR Am J Neuroradiol. 2015 Feb;36(2):269-74
pubmed: 25190202
AJNR Am J Neuroradiol. 2019 Mar;40(3):533-539
pubmed: 30765378
AJNR Am J Neuroradiol. 2015 Dec;36(12):2340-5
pubmed: 26294652
J Neurointerv Surg. 2020 Nov;12(11):1088-1093
pubmed: 31937604
N Engl J Med. 2008 Sep 25;359(13):1317-29
pubmed: 18815396
Stroke. 2020 Sep;51(9):2620-2629
pubmed: 32811386
Cerebrovasc Dis. 2016;41(5-6):298-305
pubmed: 26866928
Cerebrovasc Dis. 2016;41(5-6):306-12
pubmed: 26881779
Atherosclerosis. 2020 Nov;313:8-13
pubmed: 33002751
J Neurointerv Surg. 2015 Mar;7(3):170-5
pubmed: 25387730
Clin Neuroradiol. 2015 Dec;25(4):397-402
pubmed: 24988990
Stroke. 2011 Jun;42(6):1653-7
pubmed: 21512175